Cargando…

Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response

PURPOSE: In 2012, the CROSS trial implemented a new neoadjuvant radiochemotherapy protocol for patients with locally advanced, resectable cancer of the esophagus prior to scheduled surgery. There are only limited studies comparing the CROSS protocol with a PF-based (cisplatin/5-fluorouracil) nRCT pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenz, Eric, Weitz, Anna, Reinstaller, Therese, Hass, Peter, Croner, Roland S., Benedix, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630244/
https://www.ncbi.nlm.nih.gov/pubmed/37935904
http://dx.doi.org/10.1007/s00423-023-03091-0
_version_ 1785146008373559296
author Lorenz, Eric
Weitz, Anna
Reinstaller, Therese
Hass, Peter
Croner, Roland S.
Benedix, Frank
author_facet Lorenz, Eric
Weitz, Anna
Reinstaller, Therese
Hass, Peter
Croner, Roland S.
Benedix, Frank
author_sort Lorenz, Eric
collection PubMed
description PURPOSE: In 2012, the CROSS trial implemented a new neoadjuvant radiochemotherapy protocol for patients with locally advanced, resectable cancer of the esophagus prior to scheduled surgery. There are only limited studies comparing the CROSS protocol with a PF-based (cisplatin/5-fluorouracil) nRCT protocol. METHODS: In this retrospective, monocentric analysis, 134 patients suffering from esophageal cancer were included. Those patients received either PF-based nRCT (PF group) or nRCT according to the CROSS protocol (CROSS group) prior to elective en bloc esophagectomy. Perioperative mortality and morbidity, nRCT-related toxicity, and complete pathological regression were compared between both groups. Logistic regression analysis was performed in order to identify independent factors for pathological complete response (pCR). RESULTS: Thirty-day/hospital mortality showed no significant differences between both groups. Postoperative complications ≥ grade 3 according to Clavien-Dindo classification were experienced in 58.8% (PF group) and 47.6% (CROSS group) (p = 0.2) respectively. nRCT-associated toxicity ≥ grade 3 was 30.8% (PF group) and 37.2% (CROSS group) (p = 0.6). There was no significant difference regarding the pCR rate between both groups (23.5% vs. 30.5%; p = 0.6). In multivariate analysis, SCC (OR 7.7; p < 0.01) and an initial grading of G1/G2 (OR 2.8; p = 0.03) were shown to be independent risk factors for higher rates of pCR. CONCLUSION: We conclude that both nRCT protocols are effective and safe. There were no significant differences regarding toxicity, pathological tumor response, and postoperative morbidity and mortality between both groups. Squamous cell carcinoma (SCC) and favorable preoperative tumor grading (G1 and G2) are independent predictors for higher pCR rate in multivariate analysis.
format Online
Article
Text
id pubmed-10630244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-106302442023-11-14 Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response Lorenz, Eric Weitz, Anna Reinstaller, Therese Hass, Peter Croner, Roland S. Benedix, Frank Langenbecks Arch Surg Research PURPOSE: In 2012, the CROSS trial implemented a new neoadjuvant radiochemotherapy protocol for patients with locally advanced, resectable cancer of the esophagus prior to scheduled surgery. There are only limited studies comparing the CROSS protocol with a PF-based (cisplatin/5-fluorouracil) nRCT protocol. METHODS: In this retrospective, monocentric analysis, 134 patients suffering from esophageal cancer were included. Those patients received either PF-based nRCT (PF group) or nRCT according to the CROSS protocol (CROSS group) prior to elective en bloc esophagectomy. Perioperative mortality and morbidity, nRCT-related toxicity, and complete pathological regression were compared between both groups. Logistic regression analysis was performed in order to identify independent factors for pathological complete response (pCR). RESULTS: Thirty-day/hospital mortality showed no significant differences between both groups. Postoperative complications ≥ grade 3 according to Clavien-Dindo classification were experienced in 58.8% (PF group) and 47.6% (CROSS group) (p = 0.2) respectively. nRCT-associated toxicity ≥ grade 3 was 30.8% (PF group) and 37.2% (CROSS group) (p = 0.6). There was no significant difference regarding the pCR rate between both groups (23.5% vs. 30.5%; p = 0.6). In multivariate analysis, SCC (OR 7.7; p < 0.01) and an initial grading of G1/G2 (OR 2.8; p = 0.03) were shown to be independent risk factors for higher rates of pCR. CONCLUSION: We conclude that both nRCT protocols are effective and safe. There were no significant differences regarding toxicity, pathological tumor response, and postoperative morbidity and mortality between both groups. Squamous cell carcinoma (SCC) and favorable preoperative tumor grading (G1 and G2) are independent predictors for higher pCR rate in multivariate analysis. Springer Berlin Heidelberg 2023-11-08 2023 /pmc/articles/PMC10630244/ /pubmed/37935904 http://dx.doi.org/10.1007/s00423-023-03091-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Lorenz, Eric
Weitz, Anna
Reinstaller, Therese
Hass, Peter
Croner, Roland S.
Benedix, Frank
Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title_full Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title_fullStr Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title_full_unstemmed Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title_short Neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
title_sort neoadjuvant radiochemotherapy with cisplatin/5-flourouracil or carboplatin/paclitaxel in patients with resectable cancer of the esophagus and the gastroesophageal junction — comparison of postoperative mortality and complications, toxicity, and pathological tumor response
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630244/
https://www.ncbi.nlm.nih.gov/pubmed/37935904
http://dx.doi.org/10.1007/s00423-023-03091-0
work_keys_str_mv AT lorenzeric neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse
AT weitzanna neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse
AT reinstallertherese neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse
AT hasspeter neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse
AT cronerrolands neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse
AT benedixfrank neoadjuvantradiochemotherapywithcisplatin5flourouracilorcarboplatinpaclitaxelinpatientswithresectablecanceroftheesophagusandthegastroesophagealjunctioncomparisonofpostoperativemortalityandcomplicationstoxicityandpathologicaltumorresponse